Sickle Cell Disease (SCD)

Background: SCD is an inherited disorder that affects millions of people worldwide. The major pathophysiology of SCD is polymerization of deoxygenated haemoglobin S (HbS), leading to sickling and destruction of red blood cells (RBCs) and end-organ damage. Increasing the levels of fetal hemoglobin (HbF) are clinically beneficial with longer survival and lower pain rates in SCD patients. 

Model: Phlebotomy induced anemia.

Standard study duration: 8-10 weeks

Clinical endpoint: HCT, HGB, coagulation tests, HbF expression…

Features: Human-like anemia symptoms and markers, safety assessment, periodic treatment, secondary diseases…

For more information about these models, please contact Mr. James Song,